Advances in HIV-1 entry inhibitors: Strategies to interfere with receptor and coreceptor engagement

Current Pharmaceutical Design

Volumn 12, Issue 9, 2006, Pages 1105-1119

  Markovic, Ingrid ^a  

^a Center for Drug Evaluation and Research   (United States)

Author keywords

Antiviral therapy; CCR5; CD4; Coreceptor switch; CXCR4; Membrane fusion; Viral entry; Viral resistance

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; AMD 3465; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APLAVIROC; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; PROTEINASE INHIBITOR; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; ST 6; T 140; T 22; TENOFOVIR; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY;

ANIMALS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, HIV;

EID: 33645580897     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055822     Document Type: Review

References (156)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Markovic I, Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004; 2: 223-34.
3. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-7.
5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
6. Chernmordik LV, Leikina E, Kozlov MM, Frolov VA, Zimmerberg J. Structural intermediates in influenza haemagglutinin-mediated fusion. Mol Membr Biol 1999; 16: 33-42.
7. Markovic I, Leikina E, Zhukovsky M, Zimmerberg J, Chernomordik LV. Synchronized activation and refolding of influenza hemagglutinin in multimeric fusion machines. J Cell Biol 2001; 155: 833-44.
8. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000; 1: 40-9.
9. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004 14: 255-70.
10. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002; 159: 441-52.
11. Sodeik B. Unchain my heart, baby let me go - the entry and intracellular transport of HIV. J Cell Biol 2002; 159: 393-5.
12. Freed EO. HIV-1 and the host cell: an intimate association. Trends Microbiol 2004; 12: 170-7.
13. Ono A, Freed EO. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 2004; 78: 1552-63.
14. Starr-Spires LD, Collman RG. HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med 2002; 22: 681-701.
15. Pierson TC, Doms RW. HIV-1 entry and its inhibition. Immunol Lett 2003; 85: 113-8.
16. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92.
17. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387: 426-30.
18. Weng Y, Weiss CD. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 1998; 72: 9676-82.
19. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002; 22: 531-65.
20. Markosyan RM, Cohen FS, Melikyan GB. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell 2003; 14: 926-38.
21. Dimitrov DS. Virus entry: Molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004; 2: 109-122.
22. Mondor I, Ugolini S, Sattentau QJ. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998; 72: 3623-34.
23. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74: 1948-60.
24. Bobardt MD, Armand-Ugon M, Clotet I, Zhang Z, David G, Este JA, et al. Effect of polyanion-resistance on HIV-1 infection. Virology 2004; 325: 389-98.
25. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100: 575-85.
26. Hioe CE, Chien PC Jr, Lu C, Springer TA, Wang XH, Bandres J, Tuen M. LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 2001; 75: 1077-82.
27. Tardif MR, Tremblay MJ. Presence of host ICAM-1 in human immunodeficiency virus type 1 virions increases productive infection of CD4+ T lymphocytes by favoring cytosolic delivery of viral material. J Virol 2003; 77: 12299-309.
28. Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, Wang JM, Puri A, Blumenthal R. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000; 74: 6377-85.
29. Hammache D, Yahi N, Maresca M, Pieroni G, Fantini J. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 1999; 73: 5244-8.
30. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312: 767-8.
31. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333-48.
32. Kowalski M, Potz J, Basiripour L, Dorfman T, Gob WC, Terwilliger E, et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987; 237: 1351-5.
33. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
34. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-53.
35. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, et al. Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 2000; 97: 9026-31.
36. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-I coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
37. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb) 2003; 11: 225-36.
38. Stantchev TS, Broder CC. Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors. Cytokine Growth Factor Rev 2001; 12: 219-43.
39. Chabot DJ, Chen H, Dimitrov DS, Broder CC. N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol 2000; 74: 4404-13.
40. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-73.
41. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151: 413-423.
42. Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. Aids 1999; 13(Suppl A): S137-62.
43. Barbouche R, Miquelis R, Jones IM, Fenouillet E. J Biol Chem 2003; 278: 3131-6.
44. Gallina A, Hanley TM, Mandel R, Trahey M, Broder CC, Viglianti GA, et al. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J Biol Chem, 2002, 277: 50579-88.
45. Fenouillet E, Barbouche R, Courageot J, Miquelis R. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. J Infect Dis 2001; 183: 744-52.
46. Fenouillet E, Barbouche R, Jones IM. HIV Env reduction postreceptor binding: a new target for AIDS treatment? Blood 2004; 104: 296.
47. Markovic I, Stantchev TS, Fields KH, Tiffany LJ, Tomic M, Weiss CD, et al. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 2004; 103: 1586-94.
48. Janeway CA Jr, Travers P. In: Immunobiology, The immune system in health and disease. Garland Publishing Inc., New York and London 1997.
49. Sodroski JG. HIV-1 entry inhibitors in the side pocket. Cell 1999; 99: 243-6.
50. Cruikshank WW, Center DM, Nisar N, Wu M, Natke, B, Theodore AC, et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994; 91: 5109-13.
51. Bonnard M, Haughn L, Julius M. CD4-mediated inhibiton of IL-2 production in activated T cells. J Immunol 1999; 162: 1252-60.
52. Levesque K, Finzi A, Binette J, Cohen EA. Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res 2004; 2: 51-9.
53. Lama J. The physiological relevance of CD4 receptor down-modulation during HIV infection. Curr HIV Res 2003; 1: 167-84.
54. Tanaka M, Ueno T, Nakahara T, Sasaki K, Ishimoto A, Sakai H. Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1. Virology 2003; 311: 316-25.
55. Levesque K, Zhao YS, Cohen EA. Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem 2003; 278: 28346-53.
56. Bour S, Geleziunas R, Wainberg MA. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev 1995; 59: 63-93.
57. Arganaraz E, Cortes MJ, Leibel S, Lama J. Human immunodeficiency virus type 1 Vpr protein does not modulate surface expression of the CD4 receptor. J Virol 2002; 76: 4125-30.
58. Lin G, Baribaud F, Romano J, Doms RW, Hoxie JA. Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol 2003; 77: 931-42.
59. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, et al, Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci USA 1999; 96: 6359-64.
60. Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J, et al. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001; 75: 5230-9.
61. Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, Rucker J, et al. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci USA 1997; 94: 14742-7.
62. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87: 745-56.
63. Reeves JD, Schulz TF. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J Virol 1997; 71: 1453-65.
64. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999; 73: 8120-6.
65. Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001; 75: 2041-50.
66. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. Aids 2003; 17: 291-300.
67. Bhattacharya J, Peters PJ, Clapham PR. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vtvo. Aids 2003; 17(Suppl 4): S35-43.
68. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100: 11013-8.
69. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77: 10528-36.
70. Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2, 3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003; 46: 4236-9.
71. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004; 78: 3742-52.
72. Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331: 78-81.
73. Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331: 82-4.
74. Ashkenazi A, Smith DH, Marsters SA, Riddle L, Gregory TJ, Ho DD, et al. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci USA 1991; 88: 7056-60.
75. Klasse PJ, Moore JP. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol 1996; 70: 3668-77.
76. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990; 112: 247-53.
77. Schacker T, Collier AC, Coombs R, Unadkat JD, Fox I, Alam J, et al. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 145-52.
78. Moore JP, Burkly LC, Connor RI, Cao Y, Tizard R, Ho DD, et al. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res Hum Retroviruses 1993; 9: 529-39.
79. Arthos J, Cicala C, Steenbeke TD, Chun TW, Dela Cruz C, Hanback DB, et al. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem 2002; 277: 11456-64.
80. Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, et al. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 150-6.
81. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11: 533-9.
82. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348: 2228-38.
83. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, et al. Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542. Antimicrob Agents Chemother 2004; 48: 423-429.
84. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182: 326-9.
85. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003; 21: 71-6.
86. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992, 149: 1779-87.
87. Moore JP, Sattentau QJ, Klasse PJ, Burkly LC. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992; 66: 4784-93.
88. Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 2002; 172: 191-203.
89. Klasse PJ, Sattentau QJ. Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. AIDS Res Hum Retroviruses 1996; 12: 1015-21.
90. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286-91.
91. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 2004; 16: 1201-10.
92. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004; 78: 11807-15.
93. Jansson M, Backstrom E, Bjorndal A, Holmberg V, Rossi P, Fenyo EM, et al. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol 1999 2: 325-38.
94. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuite-maker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis 1999; 180: 1106-15.
95. Penn ML, Grivel JC, Schramm B, Goldsmith MA, Margolis L. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci USA 1999; 96: 663-8.
96. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
97. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
98. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
99. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3: 338-40.
100. Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/ Delta32 genotype is increased in hepatitis C. Gastroenterology 2002; 122: 1721-8.
101. Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998; 62: 1507-15.
102. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 2003; 100: 15276-9.
103. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96: 5698-703.
104. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000; 97: 5639-44.
105. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr Pharm Des 2004; 10: 2041-62.
106. Este JA. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003; 10: 1617-32.
107. Tagat JR, Steensma RW, McCombie SW, Nazareno DV, Lin SI, Neustadt BR, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)- methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine Nl-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem 2001; 44: 3343-6.
108. Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, et al. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1′-[(2, 4-dimethyl-3- pyridinyl)carbonyl]-4′-methyl-1, 4′- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 2001; 44: 3339-42.
109. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 12718-23.
110. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77: 5201-8.
111. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73: 4145-55.
112. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75: 579-88.
113. Meta A, Torigoe N, Ito Y, Arakaki R, Nakashima H, Sugimura K. Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1alpha-binding activity. Mol Immunol 1999; 36: 1249-54.
114. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997; 186: 1373-81.
115. Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CF 3rd. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 2000; 97: 805-10.
116. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF 3rd. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 2000; 275: 36073-8.
117. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-9.
118. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-8.
119. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-73.
120. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, Dohlman HG, et al. Identification of allosteric peptide agonists of CXCR4. J Biol Chem 2003; 278: 896-907.
121. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 2001; 82: 1807-14.
122. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38: 668-74.
123. De Vreese K, Reymen D, Griffin P, Steinkasserer A, Werner G, Bridger GJ, et al. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res 1996; 29: 209-19.
124. O'Hara BM, Olson WC. HIV entry inhibitors in clinical development. Curr Opin Pharmacol 2002; 2: 523-8.
125. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30.
126. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003; 100: 4185-90.
127. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. Aids 2002; 16: 2385-90.
128. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-8.
129. Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 2003; 13: 303-12.
130. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 2004; 11: 1703-12.
131. Fujii N, Tamamura H. Peptide-lead CXCR4 antagonists with high anti-HIV activity. Curr Opin Investig Drugs 2001; 2: 1198-202.
132. Tamamura H, Hiramatsu K, Miyamoto K, Omagari A, Oishi S, Nakashima H, et al. Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety. Bioorg Med Chem Lett 2002; 12: 923-8.
133. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 2003; 12: 185-95.
134. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999; 163: 4597-603.
135. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993; 67: 1772-7.
136. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, et al. Highly potent RANTES analogues either prevent CCR5- using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73: 3544-50.
137. Harrowe G, Cheng-Mayer C. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology 1995; 210: 490-4.
138. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 66: 6777-80.
139. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
140. Liu SL, Mittler JE, Nickle DC, Mulvania TM, Shriner D, Rodrigo AG, et al. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol 2002; 76: 10674-84.
141. Pastore C, Ramos A, Mosier DE. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004; 78: 7565-74.
142. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99: 395-400.
143. Helseth E, Olshevsky U, Furman C, Sodroski J. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 1991; 65: 2119-23.
144. Blacklow SC, Lu M, Kim PS. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 1995; 34: 14955-62.
145. Carr CM, Chaudhry C, Kim PS. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci USA 1997; 94: 14306-13.
146. Carr CM, Kim PS. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993; 73: 823-32.
147. Remeta DP, Krumbiegel M, Minetti CA, Puri A, Ginsburg A, Blumenthal R. Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry 2002; 41: 2044-54.
148. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998; 187: 1215-24.
149. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999; 73: 5577-85.
150. Liu HY, Soda Y, Shimizu N, Haraguchi Y, Jinno A, Takeuchi Y, et al. CD4-Dependent and CD4-independent utilization of coreceptors by human immunodeficiency viruses type 2 and simian immunodeficiency viruses. Virology 2000; 278: 276-88.
151. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73: 2343-9.
152. Morner A, Bjorndal A, Leandersson AC, Albert J, Bjorling E, Jansson M. CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. AIDS Res Hum Retroviruses 2002; 18: 193-200.
153. Leikina E, Ramos C, Markovic I, Zimmerberg J, Chernomordik LV. Reversible stages of the low-pH-triggered conformational change in influenza virus hemagglutinin. EMBO J 2002; 21: 5701-10.
154. Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 2004; 10(15): 1827-43.
155. Menendez-Arias L, Este JA. HIV-resistance to viral entry inhibitors. Curr Pharm Des 2004; 10(15): 1845-60.
156. Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004; 10(15): 1805-25.